142 related articles for article (PubMed ID: 21534873)
1. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
Patel SB; Gojo I; Tidwell ML; Sausville EA; Baer MR
Leuk Lymphoma; 2011 Jul; 52(7):1211-4. PubMed ID: 21534873
[TBL] [Abstract][Full Text] [Related]
2. Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era?
Bassan R
Leuk Lymphoma; 2011 Jul; 52(7):1164-5. PubMed ID: 21612380
[No Abstract] [Full Text] [Related]
3. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
4. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
5. Subdural hematomas during CML therapy with imatinib mesylate.
Song KW; Rifkind J; Al-Beirouti B; Yee K; McCrae J; Messner HA; Keating A; Lipton JH
Leuk Lymphoma; 2004 Aug; 45(8):1633-6. PubMed ID: 15370217
[TBL] [Abstract][Full Text] [Related]
6. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
Schultz KR; Bowman WP; Aledo A; Slayton WB; Sather H; Devidas M; Wang C; Davies SM; Gaynon PS; Trigg M; Rutledge R; Burden L; Jorstad D; Carroll A; Heerema NA; Winick N; Borowitz MJ; Hunger SP; Carroll WL; Camitta B
J Clin Oncol; 2009 Nov; 27(31):5175-81. PubMed ID: 19805687
[TBL] [Abstract][Full Text] [Related]
7. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Biondi A; Schrappe M; De Lorenzo P; Castor A; Lucchini G; Gandemer V; Pieters R; Stary J; Escherich G; Campbell M; Li CK; Vora A; Aricò M; Röttgers S; Saha V; Valsecchi MG
Lancet Oncol; 2012 Sep; 13(9):936-45. PubMed ID: 22898679
[TBL] [Abstract][Full Text] [Related]
8. Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment.
Riva G; Luppi M; Barozzi P; Quadrelli C; Basso S; Vallerini D; Zanetti E; Morselli M; Forghieri F; Maccaferri M; Volzone F; Del Giovane C; D'Amico R; Locatelli F; Torelli G; Comoli P; Potenza L
Blood; 2010 Feb; 115(8):1512-8. PubMed ID: 20007806
[TBL] [Abstract][Full Text] [Related]
9. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B; Pfeifer H; Goekbuget N; Beelen DW; Beck J; Stelljes M; Bornhäuser M; Reichle A; Perz J; Haas R; Ganser A; Schmid M; Kanz L; Lenz G; Kaufmann M; Binckebanck A; Brück P; Reutzel R; Gschaidmeier H; Schwartz S; Hoelzer D; Ottmann OG
Blood; 2006 Sep; 108(5):1469-77. PubMed ID: 16638934
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with imatinib combined with less intensive chemotherapy (vincristine and dexamethasone) as induction therapy in a very elderly patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Nishii K; Sakakura M; Tsukada T; Ryuu H; Katayama N
Int J Hematol; 2007 Apr; 85(3):273-4. PubMed ID: 17483068
[No Abstract] [Full Text] [Related]
12. Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ishii Y; Shoji N; Kimura Y; Ohyashiki K
Intern Med; 2006; 45(5):339-40. PubMed ID: 16596010
[No Abstract] [Full Text] [Related]
13. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Ottmann OG; Druker BJ; Sawyers CL; Goldman JM; Reiffers J; Silver RT; Tura S; Fischer T; Deininger MW; Schiffer CA; Baccarani M; Gratwohl A; Hochhaus A; Hoelzer D; Fernandes-Reese S; Gathmann I; Capdeville R; O'Brien SG
Blood; 2002 Sep; 100(6):1965-71. PubMed ID: 12200353
[TBL] [Abstract][Full Text] [Related]
14. Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Cross SA; Lyseng-Williamson KA
Drugs; 2007; 67(17):2645-54. PubMed ID: 18034597
[TBL] [Abstract][Full Text] [Related]
15. Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
Morgensztern D; Rosado MF; Raez LE; Santos ES; Cassileth PA
Leuk Lymphoma; 2005 Feb; 46(2):297-8. PubMed ID: 15621818
[No Abstract] [Full Text] [Related]
16. Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia.
Thomas D
Lancet Oncol; 2012 Sep; 13(9):860-2. PubMed ID: 22935232
[No Abstract] [Full Text] [Related]
17. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
de Labarthe A; Rousselot P; Huguet-Rigal F; Delabesse E; Witz F; Maury S; Réa D; Cayuela JM; Vekemans MC; Reman O; Buzyn A; Pigneux A; Escoffre M; Chalandon Y; MacIntyre E; Lhéritier V; Vernant JP; Thomas X; Ifrah N; Dombret H;
Blood; 2007 Feb; 109(4):1408-13. PubMed ID: 17062730
[TBL] [Abstract][Full Text] [Related]
18. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice.
Yanada M; Naoe T
Leuk Lymphoma; 2006 Sep; 47(9):1747-53. PubMed ID: 17064984
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Takeuchi M; Koseki M; Uryu H
Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B; Scheuring U; Pfeifer H; Binckebanck A; Käbisch A; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Oct; 17(10):1919-24. PubMed ID: 14513038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
